AMX0035 lower long-term risk of death in ALS

Patients with amyotrophic lateral sclerosis (ALS) randomized to receive AMX0035 (Amylyx Pharmaceuticals, Inc) had significantly lower long-term risk of death or permanent assisted ventilation (PAV) and risk of first hospitalization compared to patients treated with placebo, according to a company press release.

“We are strongly encouraged by the results from the CENTAUR trial,” said Dr Sabrina Paganoni, MD, PhD, principal investigator of the CENTAUR study, investigator at the Sean M. Healey & AMG Center for ALS at Mass General and Assistant Professor of PM&R at Harvard Medical School and Spaulding Rehabilitation Hospital in a press release. “These results show a consistent effect with AMX0035 across endpoints of survival, hospitalization and permanent ventilation. I am enthusiastic about these results which continue to support AMX0035 as a potential therapeutic for ALS.”

Data were presented in an oral session at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference held March 15-18, 2021.